KC Star Regional Stocks
Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
EDAP TMS SA (NQ: EDAP)
3.650 USD  -0.250 (-6.41%)
Streaming Delayed Price  /  Updated: 2:59 PM EDT, May 23, 2013  /  Add to My Watchlist      
View: Quote News Research
Press releases about EDAP TMS SA
 
< Previous 1 2 3 4 5 6 7 8 9 Next >
EDAP to Raise $12 Million in Registered Direct Offering
May 21, 2013
from GlobeNewswire News Releases
EDAP's Ablatherm-HIFU Demonstrates Long Term Efficacy, Durability and Reproducibility With Prospective Fourteen -Year Study
May 20, 2013
Third Long Term Study Published in 2013 Validates Ablatherm-HIFU as First Line Treatment of Prostate Cancer Read More
from GlobeNewswire News Releases
EDAP Reports 23% Increase in First Quarter 2013 Revenues
May 16, 2013
from GlobeNewswire News Releases
EDAP's Ablatherm-HIFU Receives Two Best Poster Awards at 2013 American Urological Association Annual Meeting
May 14, 2013
from GlobeNewswire News Releases
EDAP Schedules Webcast and Conference Call for First Quarter 2013 Results
May 13, 2013
from GlobeNewswire News Releases
EDAP Outlines Significant Participation at 2013 American Urological Association Annual Meeting
May 01, 2013
from GlobeNewswire News Releases
EDAP Announces 23% First Quarter 2013 Revenue Growth
April 11, 2013
from GlobeNewswire News Releases
EDAP Reports Fourth Quarter 2012 and Full Year Results
April 02, 2013
from GlobeNewswire News Releases
EDAP Receives U.S. FDA Filing Acceptance of Pre-Market Approval Application
March 28, 2013
Ablatherm(R)-HIFU PMA Application Proceeds to Substantive Review Read More
from GlobeNewswire News Releases
EDAP Introduces Focal.One(R): A New Robotic HIFU Device for Focal Therapy of Prostate Cancer
March 14, 2013
Focal.One World Premiere at European Association of Urology Annual Congress Read More
from GlobeNewswire News Releases
EDAP Schedules Webcast and Conference Call for Fourth Quarter and Full Year 2012 Results
March 12, 2013
from GlobeNewswire News Releases
EDAP Receives U.S. FDA Administrative Acceptance Review Notification for Ablatherm(R)-HIFU Pre-Market Approval Application
March 07, 2013
PMA for Treatment of Low Risk, Localized Prostate Cancer Read More
from GlobeNewswire News Releases
NASDAQ Stocks Announcements: (NASDAQ: EDAP), (NASDAQ: PSDV)
February 25, 2013
from SBWire Direct - Latest Press Releases
EDAP's Ablatherm-HIFU Offers Reliable Therapy for Localized Prostate Cancer
February 22, 2013
Munich Study Concludes 15 Year Outcome Data May Warrant Closing of Investigational Phase for HIFU Read More
from GlobeNewswire News Releases
EDAP's Ablatherm-HIFU Demonstrates Long-Term Efficacy and Safety Over Fourteen-Year Period
February 08, 2013
Longest Retrospective Study of HIFU Patients to Date Published Confirms Benefits of Treatment Read More
from GlobeNewswire News Releases
EDAP Submits U.S. FDA Pre-Market Approval Application for Ablatherm(R)-HIFU for Treatment of Low Risk, Localized Prostate Cancer
February 01, 2013
from GlobeNewswire News Releases
EDAP Reports 25% Year-Over-Year Revenue Growth for Fourth Quarter 2012
January 22, 2013
from GlobeNewswire News Releases
The Real Story Behind EDAP, VVI, CHTP and USU
January 11, 2013
from Marketwired News Releases
Perfect Trade Setups, How to Play CHTP, EDAP, ACAD and CHKR
January 08, 2013
from Marketwired News Releases
Intra-Day Trend Analysis Reports Investors Should Know About: (NASDAQ: EDAP), (NYSE: HMA)
December 20, 2012
from SBWire Direct - Latest Press Releases
The Real Story Behind ALTE, EDAP, NEPT and PGNX
December 20, 2012
from Marketwired News Releases
EDAP Reports Third Quarter 2012 Results
November 21, 2012
from GlobeNewswire News Releases
EDAP Schedules Webcast and Conference Call for Third Quarter 2012 Results
November 07, 2012
from GlobeNewswire News Releases
EDAP Highlights HIFU Expertise at Third International Symposium on Focused Ultrasound in Washington, D.C.
October 25, 2012
Expanding Interest for HIFU Use in Treating Prostate and Liver Cancer Read More
from GlobeNewswire News Releases
EDAP Appoints Experienced Lithotripsy Expert to Increase U.S. Sales
October 09, 2012
Strengthens Sales Team In Line With Strategy to Focus on U.S. Urology Market Read More
from GlobeNewswire News Releases
EDAP Reports Second Quarter 2012 Revenues Up 61%
August 30, 2012
from GlobeNewswire News Releases
EDAP Retains Greenleaf Health as Strategic Advisor on U.S. FDA Submission
August 29, 2012
Strengthens Team for Final Stages of Ablatherm-HIFU Phase II/III Clinical Trial for Prostate Cancer Read More
from GlobeNewswire News Releases
EDAP Completes Follow-Up Phase and Data Collection for FDA ENLIGHT Trial
August 17, 2012
from GlobeNewswire News Releases
EDAP Schedules Webcast and Conference Call for Second Quarter 2012 Results
August 03, 2012
from GlobeNewswire News Releases
EDAP Reports Revenue Increase of 61% Year-Over-Year for Second Quarter 2012
July 25, 2012
from GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here